title: Effects of pirfenidone and dermoid cyst fluid on adhesion formation.
abstract: OBJECTIVE
  To evaluate the effects of pirfenidone and human dermoid cyst fluid on adhesion formation in a rat model.
  
  
  METHODS
  A prospective, blinded, controlled study.
  
  
  METHODS
  Sprague-Dawley white rats in a conventional laboratory setting.
  
  
  METHODS
  Rats were divided into four groups according to the type of solution tested (dermoid fluid, 0.05 mg of pirfenidone, normal saline, and a combination of dermoid fluid and pirfenidone). In the first experiment, the solution (0.5 mL) was injected intraperitoneally. In the second experiment, the solution was instilled intraperitoneally after a standardized injury to the right uterine horn. The degree of adhesion formation was evaluated 2 weeks after the initial surgery.
  
  
  RESULTS
  Human dermoid cyst fluid caused adhesion in 4 of 10 intact rats and in 9 of 10 standardized injured rats. Pirfenidone did not decrease adhesion formation. No adhesion was found after injection of saline or pirfenidone in intact rats. The mean +/- SEM adhesion score in standardized injured rats was higher in the dermoid group (4.6 +/- 0.6) than in the pirfenidone group (2.8 +/- 0.7) or the saline group (3.8 +/- 0.5). The mean +/- SEM adhesion score in intact rats was 0.6 +/- 0.3 after dermoid fluid injection and after dermoid instillation in standardized injured rats was 4.6 +/- 0.6.
  
  
  CONCLUSIONS
  Human dermoid fluid causes adhesion formation even in intact rats, and the adhesion is worse in the presence of serosal injury. Intraperitoneal pirfenidone does not decrease adhesion formation.
authors.affiliation: Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada.
authors.forename: S
authors.initials: S
authors.lastname: al-Took
authors.forename: C
authors.initials: C
authors.lastname: Murray
authors.forename: T
authors.initials: T
authors.lastname: Tulandi
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D003884:Dermoid Cyst / Q000737:chemistry* / Q000503:physiopathology / Q000601:surgery; D004195:Disease Models, Animal; D005260:Female; D007274:Injections, Intraperitoneal; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000503:physiopathology / Q000601:surgery; D011446:Prospective Studies; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000267:Tissue Adhesions / Q000209:etiology / Q000517:prevention & control; D014591:Uterine Diseases / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011728:Pyridones; C093844:pirfenidone